Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.6, pp.1195-1196, 2019 (SCI-Expanded, Scopus)
- Publication Type: Article / Letter
- Volume: 83 Issue: 6
- Publication Date: 2019
- Doi Number: 10.1007/s00280-019-03810-9
- Journal Name: CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1195-1196
- Hacettepe University Affiliated: Yes
Abstract
Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability.